<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36068">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637024</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2015-OPAR</org_study_id>
    <nct_id>NCT02637024</nct_id>
  </id_info>
  <brief_title>Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation</brief_title>
  <acronym>OPAR</acronym>
  <official_title>A Phase II Randomized Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation (OPAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre randomized phase II trial in women with invasive carcinoma of the
      breast with negative axillary nodes or Ductal Carcinoma In-situ (DCIS) treated by Breast
      Conserving Surgery (BCS). Eligible, consenting patients will be randomly allocated to
      receive radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated
      Partial Breast Irradiation (APBI) 30 Gray (Gy) in 5 daily fractions of 6Gy or 27.5Gy in 5
      daily fractions of 5.5Gy over one week. Patients will be followed at 12, 24, 36 and 60
      months post randomization. Cosmetic outcome will be measured using photographs and evaluated
      by a panel of trained radiation oncologists. Radiation toxicity will be assessed using
      National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with invasive carcinoma of the breast with negative axillary nodes or DCIS, following
      BCS and/or chemotherapy, who meet the inclusion criteria will be screened and approached for
      eligibility assessment and potential study enrollment. All potentially eligible and
      consenting patients who do not meet the exclusion criteria will have a Computed Tomography
      (CT) simulation of the ipsilateral breast prior to randomization. All cases will be required
      to be planned prior to the randomization to ensure that dosimetric coverage and normal
      tissue restrictions can be met. If the seroma is not clearly visible or if the surgical
      clips do not adequately identify a previous surgical cavity, the patient will not be
      eligible for randomization.

      Eligible, consenting patients will be randomly allocated to receive radiotherapy of 3DCRT
      APBI 30Gy in 5 daily fractions of 6Gy or 27.5Gy in 5 daily fractions of 5.5Gy over one week.
      Patients will be followed at 12, 24, 36 and 60 months post randomization. Cosmetic outcome
      will be measured using photographs and evaluated by a panel of trained radiation oncologists
      using the EORTC Breast Cosmetic Rating System. Radiation toxicity will be assessed using the
      NCI CTCAE version 4.02. The primary outcome is adverse cosmetic outcome at 2 years. The
      trial will be conducted in clinical centres within Canada.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse cosmetic outcome using the EORTC Breast Cosmetic Rating System</measure>
    <time_frame>2 years post randomization</time_frame>
    <description>The primary outcome is adverse cosmesis assessed at 2 years post randomization as determined by photographic assessment. The cosmetic outcome will be assessed by a panel of 3 trained radiation oncologists who are unaware of treatment allocation, using the EORTC Breast Cosmetic Rating System for cosmetic results for breast conserving treatment. The treated breast is compared with the untreated breast for size, shape, location of the areola/nipple, appearance of the surgical scar, presence of telangiectasia, and a global cosmetic score based on these factors. Characteristics are graded on a 4-point scale: 0 = excellent; 1 = good; 2 = fair; 3 = poor. A global cosmetic score of fair or poor will be used as the primary outcome of adverse cosmesis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic deterioration (defined as any adverse change in the global cosmetic score)</measure>
    <time_frame>Baseline to two years</time_frame>
    <description>defined as any adverse change in the global cosmetic score from baseline to 2 years. Subjects with global cosmetic scores that were stable or improved from baseline to 2 years will be scored as 'no deterioration'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.02</measure>
    <time_frame>12, 24, 36 and 60 months</time_frame>
    <description>defined as breast induration/fibrosis, shrinkage, and telangiectasia, which will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.02.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral breast tumour recurrence (IBTR)</measure>
    <time_frame>Ongoing throughout study up to 5 years</time_frame>
    <description>defined as recurrent invasive or in situ cancer in the ipsilateral breast including the axillary tail. Histological evidence of local recurrence will be required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Ongoing throughout study up to 5 years</time_frame>
    <description>defined as the time from randomization to the time of documented recurrent disease in the ipsilateral breast or regional nodes (supraclavicular, axillary or internal mammary) or distant sites (e.g. bone, liver, lung or brain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of death up to 5 years</time_frame>
    <description>defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Breast Cancer</condition>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>APBI: 30 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APBI: 27.5 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>APBI: 30 Gy</intervention_name>
    <description>30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.</description>
    <arm_group_label>APBI: 30 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>APBI: 27.5 Gy</intervention_name>
    <description>27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.</description>
    <arm_group_label>APBI: 27.5 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with a new histological diagnosis of DCIS or invasive carcinoma of the breast
             with no evidence of metastatic disease.

          2. Treated by BCS with microscopically clear resection margins for invasive and
             non-invasive disease (or no residual disease on re-excision).

          3. Negative axillary node involvement, including positive cells only identified by
             Immunohistochemistry (IHC) as determined either by sentinel node biopsy or axillary
             node dissection, or a clinical exam for patients with DCIS only.

        Exclusion Criteria:

          1. Age less than 50 years

          2. Known to be Breast Cancer Type 1 Susceptibility Protein (BRCA 1) and/or Breast Cancer
             Type 2 Susceptibility Protein (BRCA 2) positive

          3. Tumour size &gt;3 cm in greatest diameter on pathological examination (including the
             invasive and non-invasive components)

          4. Tumour histology limited to lobular carcinoma only

          5. Grade III invasive breast carcinoma or nuclear grade III for patients with DCIS alone

          6. Triple negative invasive breast cancer

          7. Her2+ve invasive breast cancer that will not receive Herceptin

          8. Bilateral invasive malignancy of the breast (synchronous or metachronous)

          9. More than one primary tumor in different quadrants of the same breast

         10. Presence of an ipsilateral breast implant or pacemaker

         11. Status for adjuvant systemic therapy not determined

         12. For patients not treated with adjuvant chemotherapy, unable to commence radiation
             therapy:

               1. within 12 weeks of the last surgical procedure on the breast, or

               2. within 8 weeks of the last dose of chemotherapy

         13. Inability to localize surgical cavity on CT (i.e. no evidence of surgical clips or
             seroma)

         14. Inability to adequately plan the patient for the experimental technique.

         15. Previous or concurrent malignancies except:

               1. Non-melanoma skin cancer

               2. Carcinoma in-situ of the cervix

               3. Invasive carcinoma of the cervix, endometrium, colon and thyroid, treated 5
                  years prior to study entry with no evidence of disease

         16. Serious non-malignant disease (e.g. cardiovascular, pulmonary, systemic lupus
             erythematosus (SLE), scleroderma) which would preclude definitive radiation
             treatment.

         17. Current pregnancy or lactating.

         18. Psychiatric or addictive disorders which would preclude obtaining informed consent or
             adherence to the protocol.

         19. Geographic inaccessibility for follow-up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Do-Hoon Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelley Chambers, MA</last_name>
    <phone>905-387-9711</phone>
    <phone_ext>64510</phone_ext>
    <email>chamberss@hhsc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna McCarty</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42605</phone_ext>
    <email>mccartyd@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Simcoe Muskoka Regional Cancer Centre, Royal Victoria Hospital</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Marsh-Gray</last_name>
      <phone>705-728-9090</phone>
      <phone_ext>43340</phone_ext>
      <email>marshk@rvh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Christiaan Stevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Shing</last_name>
      <phone>905-387-9711</phone>
      <phone_ext>64406</phone_ext>
      <email>shing@hhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Kelleher</last_name>
      <phone>905-387-9711</phone>
      <phone_ext>64430</phone_ext>
      <email>lkellehe@hhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Do-Hoon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Wellhauser</last_name>
      <phone>519-749-4370</phone>
      <phone_ext>2447</phone_ext>
      <email>elyse.wellhauser@grhosp.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Robyn Kraft</last_name>
      <phone>519-749-4370</phone>
      <phone_ext>2447</phone_ext>
      <email>robyn.pawluk@grhosp.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ramana Rachakonda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program; London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Hewett</last_name>
      <phone>519-685-8618</phone>
      <email>lorraine.hewett@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Francisco Perera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre, Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hew-Shue</last_name>
      <phone>416-480-5000</phone>
      <phone_ext>81467</phone_ext>
      <email>mark.hew-shue@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Leila Malek</last_name>
      <phone>416-480-5000</phone>
      <phone_ext>2750</phone_ext>
      <email>leila.malek@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Clinansmith</last_name>
      <phone>519-253-5253</phone>
      <phone_ext>58571</phone_ext>
      <email>donna.clinansmith@wrh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kailey Huot</last_name>
      <phone>519-253-5253</phone>
      <phone_ext>58572</phone_ext>
      <email>kailey.huot@wrh.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Roy-Huneault</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>3227</phone_ext>
      <email>lroyhuneault.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Fortin</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>5915</phone_ext>
      <email>jfortin2.hmr@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Yassa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Centre Hospitalier de L'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trudel</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>26906</phone_ext>
      <email>diane.dt.trudel.chum@ssss.gouv.qc</email>
    </contact>
    <investigator>
      <last_name>Sophie Lavertu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUQ Pavillon Hotel-Dieu Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Allard</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>16730</phone_ext>
      <email>josee.allard@chudequebec.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Andree Lojoie</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>16739</phone_ext>
      <email>lojoie.marie-andree@mail.chudquebec.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle Germaine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUS - Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Couture</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>14311</phone_ext>
      <email>socouture.chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie Larouche</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>18429</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Sawyna Provencher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>December 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>DCIS</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Partial breast irradiation</keyword>
  <keyword>Radiation fractions</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
